Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial
Authors
Keywords
Cobicistat, Darunavir, Safety, Efficacy, Virology, Pharmacokinetics
Journal
AIDS Research and Therapy
Volume 11, Issue 1, Pages 39
Publisher
Springer Nature
Online
2014-12-02
DOI
10.1186/1742-6405-11-39
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bioequivalence of a darunavir/cobicistat fixed-dose combination tablet versus single agents and food effect in healthy volunteers
- (2014) Thomas N Kakuda et al. ANTIVIRAL THERAPY
- Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers
- (2014) Thomas N. Kakuda et al. JOURNAL OF CLINICAL PHARMACOLOGY
- A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection
- (2013) Andrew Zolopa et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection
- (2013) Jürgen K. Rockstroh et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A Randomized, Double-Blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Single-Tablet Regimen Efavirenz/Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection
- (2013) David A. Wohl et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results
- (2013) Joel E. Gallant et al. JOURNAL OF INFECTIOUS DISEASES
- Impact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, antiretroviral-naïve HIV patients
- (2012) A Buscher et al. INTERNATIONAL JOURNAL OF STD & AIDS
- Effect of Cobicistat on Glomerular Filtration Rate in Subjects With Normal and Impaired Renal Function
- (2012) Polina German et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
- (2012) Paul E Sax et al. LANCET
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
- (2012) Edwin DeJesus et al. LANCET
- Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection
- (2011) Calvin Cohen et al. AIDS
- Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients
- (2011) Pedro Cahn et al. AIDS
- Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection
- (2011) Richard Elion et al. AIDS
- Ritonavir-boosted protease inhibitors in HIV therapy
- (2011) Mark W. Hull et al. ANNALS OF MEDICINE
- Factors Associated with Complete Adherence to HIV Combination Antiretroviral Therapy
- (2011) Timothy Juday et al. HIV CLINICAL TRIALS
- Postprandial lipid effects of low-dose ritonavir vs. raltegravir in HIV-uninfected adults
- (2010) Katherine Samaras et al. AIDS
- Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer
- (2010) Lianhong Xu et al. ACS Medicinal Chemistry Letters
- Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48
- (2009) Roberto Ortiz et al. AIDS
- Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis
- (2009) Anthony M Mills et al. AIDS
- Pharmacokinetics and Pharmacodynamics of GS-9350: A Novel Pharmacokinetic Enhancer Without Anti-HIV Activity
- (2009) A A Mathias et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Absorption, Metabolism, and Excretion of Darunavir, a New Protease Inhibitor, Administered Alone and with Low-Dose Ritonavir in Healthy Subjects
- (2009) M. Vermeir et al. DRUG METABOLISM AND DISPOSITION
- Pharmacokinetics, Efficacy, and Safety of Darunavir/Ritonavir 800/100 mg Once-Daily in Treatment-Naïve and -Experienced Patients
- (2009) Marta Boffito et al. HIV CLINICAL TRIALS
- Induction Effects of Ritonavir: Implications for Drug Interactions
- (2008) Michelle M Foisy et al. ANNALS OF PHARMACOTHERAPY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started